Read by QxMD icon Read

Papillomavirus Research

Anne Hammer, Maurits Nc de Koning, Jan Blaakaer, Torben Steiniche, John Doorbar, Heather Griffin, Else Mejlgaard, Hans Svanholm, Wim Gv Quint, Patti E Gravitt
In this study, we aimed to provide molecular evidence of HPV latency in humans and discuss potential challenges of conducting studies on latency. We analyzed the entire cervix of two women who underwent hysterectomy unrelated to cervical abnormality. The cervices were sectioned into 242 and 186 sets respectively, and each set was tested separately for HPV using the SPF10-PCR-DEIA-LiPA25 system. To identify whether there was any evidence of transforming or productive infection, we used the biomarkers E4 and P16INK4a to stain slides immediately adjacent to HPV positive sections...
February 14, 2019: Papillomavirus Research
Jennifer Luff, Michelle Mader, Peter Rowland, Monica Britton, Joseph Fass, Hang Yuan
Papillomaviruses infect humans and animals, most often causing benign proliferations on skin or mucosal surfaces. Rarely, these infections persist and progress to cancer. In humans, this transformation most often occurs with high-risk papillomaviruses, where viral integration is a critical event in carcinogenesis. The first aim of this study was to sequence the viral genome of canine papillomavirus (CPV) 16 from a pigmented viral plaque that progressed to metastatic squamous cell carcinoma in a dog. The second aim was to characterize multiple viral genomic deletions and translocations as well as host integration sites...
February 13, 2019: Papillomavirus Research
Halimatou Diop, Kaylin Beiter, Tarik Gheit, Aissatou Sow, Aboubacry Dramé, Sandrine McKay-Chopin, Massimo Tommasino, Cheikh Saad Bouh Boye, Bakary Sylla, Coumba Touré Kane
OBJECTIVES: Several studies have documented the HPV genotypes in the Senegalese general population. The objective was to explore the HPV genotype distribution in Senegalese FSWs in order to assess the potential relevance of currently-available vaccines. METHODS: Vaginal swabs samples collected as part of the National Integrated Biological and Behavioral Survey in 14 regions throughout the country were randomly selected for HPV testing using bead-based multiplex genotyping (TS-MPG)...
February 13, 2019: Papillomavirus Research
Gary M Clifford, Vanessa Tenet, Damien Georges, Laia Alemany, Miquel Angel Pavón, Zigui Chen, Meredith Yeager, Michael Cullen, Joseph F Boland, Sara Bass, Mia Steinberg, Tina Raine-Bennett, Thomas Lorey, Nicolas Wentzensen, Joan Walker, Rosemary Zuna, Mark Schiffman, Lisa Mirabello
BACKGROUND: Human papillomavirus (HPV)16 can be separated into genetic sub-lineages (A1-4, B1-4, C1-4, D1-4) which may have differential cervical cancer risk. METHODS: A next-generation sequencing assay was used to whole-genome sequence 7116 HPV16-positive cervical samples from well-characterised international epidemiological studies, including 2076 controls, 1878 squamous cell carcinoma (SCC) and 186 adenocarcinoma/adenosquamous cell carcinoma (ADC), and to assign HPV16 sub-lineage...
February 6, 2019: Papillomavirus Research
Karin Neukam, Yusnelkis Milanés Guisado, María Fontillón, Laura Merino, César Sotomayor, Nuria Espinosa, Luis F López-Cortés, Pompeyo Viciana
OBJECTIVE: To determine the required learning time for high-resolution anoscopy (HRA)-guided biopsy to detect histological high-risk squamous intraepithelial lesions (hHSIL) and to identify factors that impact on the training process. METHODS: All HIV-infected, screening-naïve men-who-have-sex-with-men who underwent HRA conducted by one single observer from 2010-2017 in a Spanish HIV-outpatient clinic were analysed. RESULTS: Eighty-five (14...
February 1, 2019: Papillomavirus Research
Partha Basu, Richard Muwonge, Neerja Bhatla, Bhagwan M Nene, Smita Joshi, Pulikottil O Esmy, Usha Rani Reddy Poli, Geeta Joshi, Yogesh Verma, Eric Zomawia, Surendra S Shastri, Sharmila Pimple, Devasena Anantharaman, Priya R Prabhu, Sanjay Hingmire, Catherine Sauvaget, Eric Lucas, Michael Pawlita, Tarik Gheit, Kasturi Jayant, Sylla G Malvi, Maqsood Siddiqi, Angelika Michel, Julia Butt, Subha Sankaran, Thiraviam Pillai Rameshwari Ammal Kannan, Rintu Varghese, Uma Divate, Martina Willhauck-Fleckenstein, Tim Waterboer, Martin Müller, Peter Sehr, Shachi Vashist, Gauravi Mishra, Radhika Jadhav, Ranjit Thorat, Massimo Tommasino, M Radhakrishna Pillai, Rengaswamy Sankaranarayanan
Earlier publication from the ongoing multi-centric study of the International Agency for Research on Cancer to evaluate less than three doses of the quadrivalent Human Papillomavirus (HPV) vaccine in India amongst unmarried girls demonstrated non-inferior total antibody titres, neutralizing antibody titres and antibody avidity in 2-dose recipients compared to 3-dose recipients at 15-18 years of age [Bhatla et al., 2018]. The number of participants recruited at 15-18 years of age was 1,515 and 1,795 in the 3-dose and the 2-dose groups respectively...
January 31, 2019: Papillomavirus Research
Jessica A Kahn, Marvin Belzer, Xiaofei Chi, Jeannette Lee, Aditya H Gaur, Kenneth Mayer, Jaime Martinez, Donna C Futterman, Elizabeth A Stier, Mary E Paul, Elizabeth Y Chiao, Daniel Reirden, Steven E Goldstone, Ana P Ortiz Martinez, Edward R Cachay, Luis F Barroso, Maria Da Costa, Craig M Wilson, Joel M Palefsky
The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012-2015 among men who have sex with men 18-26 years of age enrolled in a vaccine trial (N=145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine...
January 15, 2019: Papillomavirus Research
Chris J L M Meijer
No abstract text is available yet for this article.
January 9, 2019: Papillomavirus Research
Amrei Krings, Gifty Boateng, Priscilla Dunyo, Joseph E Amuah, Rashid A Adams, Lois Adunyame, Dinah O Nkansah, Comfort M Wormenor, Benjamin T Hansen, Isaac Gedzah, Richard H Asmah, Edwin K Wiredu, Andreas M Kaufmann
Persistent Human Papillomavirus (HPV) infection is a prerequisite for cervical cancer development. Few studies investigate clearance of high-risk (hr) HPV in low-and-middle-income countries. Our study investigated HPV clearance and persistence over 4 years in women from North Tongu District, Ghana. In 2010/2011, cervical swabs of 500 patients were collected and HPV genotyped (nested multiplex PCR) in Accra, Ghana. In 2014, 104 women who previously tested positive for hr-HPV and remained untreated were re-tested for HPV...
January 6, 2019: Papillomavirus Research
Y T Kim, Beatriz Serrano, J K Lee, H Lee, S W Lee, Crystal Freeman, Jin-Kyoung Oh, Laia Alemany, Francesc-Xavier Bosch, Laia Bruni
BACKGROUND: We aimed to review the burden and the potential impact of HPV vaccines on HPV-related diseases in the Republic of Korea and to discuss cervical cancer prevention in this country. METHODS: Cancer burden statistics were retrieved from GLOBOCAN-2018 and Statistics Korea. HPV disease burden was assessed via systematic review. Vaccine types relative contribution (RC) was estimated using data from an international project using formalin-fixed paraffin-embedded specimens...
December 29, 2018: Papillomavirus Research
Linda K Ko, Victoria M Taylor, Farah Bille Mohamed, H Hoai Do, Fanaye A Gebeyaw, Anisa Ibrahim, Ahmed A Ali, Rachel L Winer
BACKGROUND: HPV vaccine studies in East African communities are few and focus mainly on Somali women and girls. We examined how HPV vaccine perceptions and uptake are shaped among Somali, Ethiopian, and Eritrean mothers. METHODS: We convened three focus groups in Somali, Amharic, and Tigrinya with mothers of 11-17 year old children. The Socio-Context Framework (social, cultural, and religious factors) and Andersen's Behavioral Model (predisposing, enabling, and need for care factors) informed question development...
December 27, 2018: Papillomavirus Research
Katrine Fuglsang, Jan Blaakaer, Lone Kjeld Petersen, Else Mejlgaard, Anne Hammer, Torben Steiniche
OBJECTIVES: The present study investigated Human Papillomavirus (HPV) DNA genotyping in primary tumor, pelvic lymph nodes (PLN) and recurrence in early-stage cervical cancer patients. METHODS: We conducted a hospital-based case-control study. From 2003 to 2015, 282 patients underwent surgery for cervical cancer in the Department of Gynecology, Aarhus University Hospital, Denmark. Twenty-nine recurrent cases were identified. HPV DNA genotyping was performed on formalin-fixed, paraffin-embedded tissue specimens from the primary tumor, PLN, and recurrent disease...
December 14, 2018: Papillomavirus Research
Gabriella Lillsunde Larsson, Malin Kaliff, Bengt Sorbe, Gisela Helenius, Mats G Karlsson
Vulvar carcinoma is the fourth most common gynecological malignancy. Two separate carcinogenic pathways are suggested, where one is associated with the human papillomavirus (HPV) and HPV16 the most common genotype. The aim of this study was to evaluate HPV-markers in a set of primary tumors, metastases and recurrent lesions of vulvar squamous cell carcinomas (VSCC). Ten HPV16-positive VSCC with metastatic regional lymph nodes, distant lymphoid/hematogenous metastases or local recurrent lesions were investigated for HPV genotype, HPV16 variant, HPV16 viral load, HPV16 integration and HPV16 E2BS3 and 4 methylation...
December 2018: Papillomavirus Research
Pamela J Toliman, John M Kaldor, Steven G Badman, Josephine Gabuzzi, Selina Silim, Antonia Kumbia, Benny Kombuk, Zure Kombati, Gloria Munnull, Rebecca Guy, Lisa M Vallely, Angela Kelly-Hanku, Handan Wand, Claire Ryan, Grace Tan, Julia Brotherton, Marion Saville, Glen D L Mola, Suzanne M Garland, Sepehr N Tabrizi, Andrew J Vallely
The performance of different clinical screening algorithms comprising point-of-care HPV-DNA testing using self-collected vaginal ('V') specimens, and visual inspection of the cervix with acetic acid (VIA) was evaluated in Papua New Guinea. Women aged 30-59 years provided V specimens that were tested at point-of-care using the Xpert HPV Test (Cepheid, Sunnyvale, CA). A clinician-collected cervical ('C') specimen was then collected for point-of-care Xpert testing, and liquid-based cytology (LBC). Following this, VIA examination was conducted, blind to HPV test results, and ablative cervical cryotherapy provided if indicated...
December 2018: Papillomavirus Research
Carrie R Innes, Peter H Sykes, Dianne Harker, Jonathan A Williman, Rachael A Van der Griend, Martin Whitehead, Merilyn Hibma, Beverley A Lawton, Peter Fitzgerald, Narena M Dudley, Simone Petrich, Jim Faherty, Cecile Bergzoll, Lois Eva, Lynn Sadler, Bryony J Simcock
In 2008, a quadrivalent human papillomavirus (HPV) vaccine (genotypes 6, 11, 16, 18) became available in New Zealand. This study investigated whether the proportion of cervical intraepithelial neoplasia grade 2 (CIN2) lesions associated with HPV genotypes 16 and 18 changed over time in young women recruited to a prospective CIN2 observational management trial (PRINCess) between 2013 and 2016. Partial HPV genotyping (16, 18, or other high risk HPV) was undertaken on n = 392 women under 25 years (mean age 21...
December 2018: Papillomavirus Research
Tuddow Thaiwong, Dodd G Sledge, Annabel G Wise, Katherine Olstad, Roger K Maes, Matti Kiupel
Canine oral papillomavirus (CPV1, also known as COPV), the most common cause of non-neoplastic papillomas, has not been shown to cause squamous cell carcinomas (SCC). Furthermore, malignant transformation of benign papillomas to SCC has only been reported in a single group of dogs with severe combined immunodeficiency infected with CPV2. Here, we report a series of 7 dogs with benign CPV1-associated papillomas with histologic evidence of CPV1 causing malignant transformation to carcinoma in situ and ultimately SCC...
November 9, 2018: Papillomavirus Research
Tumelo R Sekee, Felicity J Burt, Dominique Goedhals, Jacqueline Goedhals, Yuri Munsamy, Riaz Y Seedat
BACKGROUND: Most tumours of the head and neck are attributable to smoking and alcohol use, but an increasing proportion of head and neck tumours are caused by human papillomaviruses (HPVs). The aim of this study was to use in house molecular assays to detect and genotype HPV in biopsies from patients with histologically confirmed head and neck squamous cell carcinomas. In addition, the results were compared with p16 immunohistochemistry staining, which has been described as a potential marker for HPV infection...
November 1, 2018: Papillomavirus Research
Jinichi Sakamoto, Shoji Kamiura, Kaori Okayama, Mitsuaki Okodo, Takeo Shibata, Yasuhiro Osaka, Satoko Fujita, Emi Takata, Hiroaki Takagi, Masahiro Takakura, Toshiyuki Sasagawa
To elucidate oncogenic human papilloma virus (HPV) types in Japan, HPV genotyping was performed in 1526 cervical intraepithelial neoplasia (CIN) and 371 invasive cervical cancer (ICC) patients with the novel Genosearch-31+5 HPV test. The HPV-positive rates were 89.3% and 90.8% in CIN and ICC. Regarding single-type infections, 13 internationally recognized high-risk (13HR) types excluding HPV 35, and probably HR HPV 53, 67, 69, and 70 were identified in ICC, suggesting that all these types may be oncogenic. HPV16 and 18 were identified in both SCC and adenocarcinoma (ADC)...
October 26, 2018: Papillomavirus Research
Sally Peprah, Jenell S Coleman, Anne F Rositch, Christopher J Vanden Bussche, Richard Moore, Gypsyamber D'Souza
Frequent Pap testing is recommended among women living with HIV (WLWH) due to their elevated risk for cervical cancer. However, there are few recent longitudinal evaluations of utilization and determinants of Pap testing among WLWH. Medical and pathology records of WLWH seen at Johns Hopkins Hospital between 2005 and 2014 were assessed using Prentice, Williams, Peterson models. Of 554 WLWH in care for ≥ 18 months, 79% received Pap testing, however only 11% consistently received Pap testing at the recommended interval...
October 25, 2018: Papillomavirus Research
Katherine E Gallagher, Helen Kelly, Naomi Cocks, Sandra Dixon, Sandra Mounier-Jack, Natasha Howard, Deborah Watson-Jones
BACKGROUND: The World Health Organization (WHO) recommends a 2-dose HPV vaccine schedule for girls aged 9-14 years. As randomised controlled trials assessing the immunogenicity and efficacy of a 1-dose schedule are ongoing, we interviewed immunisation programme managers and advisors in low and middle-income countries (LMIC) about a hypothetical, future reduction in the HPV vaccine schedule. METHODS: We conducted semi-structured interviews with LMIC immunisation programme managers and national immunisation technical advisory group members (key informants; KIs) in 2017, recruited for their knowledge/experience in national HPV vaccine policy and provision...
October 21, 2018: Papillomavirus Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"